Yantai Yuhuangding Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.ytyhdyy.com
Clinical Trials
15
Active:0
Completed:3
Trial Phases
3 Phases
Phase 1:3
Phase 2:1
Not Applicable:8
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Not Applicable
8 (66.7%)Phase 1
3 (25.0%)Phase 2
1 (8.3%)Sacituzumab Tirumotecan Combined With Pembrolizumab for Neoadjuvant Treatment of TNBC Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Neoadjuvant TherapyStage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
- Interventions
- Drug: Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Yantai Yuhuangding Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT07054242
- Locations
- 🇨🇳
Department of Breast Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong, China
CPVI Alone Versus CPVI Plus Low-Voltage Areas Ablation During SR Versus CPVI Plus Low-Voltage Areas Ablation During AF for the Treatment of CAF
Not Applicable
Not yet recruiting
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Yantai Yuhuangding Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06499818
The Application of Emotion Release Technology in Anxiety Patients Before Daytime Thyroid Surgery
Not Applicable
Completed
- Conditions
- AnxietyPreoperative Nursing CareEmotional Freedom TechniqueDay Surgery
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Yantai Yuhuangding Hospital
- Target Recruit Count
- 237
- Registration Number
- NCT06388005
- Locations
- 🇨🇳
Yantai Yuhuangding Hospital, Yantai, Shandong, China
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Yantai Yuhuangding Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05800756
- Locations
- 🇨🇳
Yantai Yuhuangding Hospital, Yantai, Shandong, China
Predictive Model for Pain After TACE
Completed
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Yantai Yuhuangding Hospital
- Target Recruit Count
- 228
- Registration Number
- NCT05545046
- Locations
- 🇨🇳
Yuhuangding Hospital, Yantai, Shandong, China
- Prev
- 1
- 2
- 3
- Next
News
No news found